Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1409 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 
 

LETTER TO THE EDITOR Table of Contents   
Year : 2008  |  Volume : 19  |  Issue : 6  |  Page : 983-984
Can the principle of "LYFT" help objectively in timing renal transplantation therapy for the CKD patients?


Consultant Nephrologist, King Fahad Specialist Hospital, P.O. Box 15215, Dammam 31444, Saudi Arabia

Click here for correspondence address and email
 

How to cite this article:
Abutaleb N. Can the principle of "LYFT" help objectively in timing renal transplantation therapy for the CKD patients?. Saudi J Kidney Dis Transpl 2008;19:983-4

How to cite this URL:
Abutaleb N. Can the principle of "LYFT" help objectively in timing renal transplantation therapy for the CKD patients?. Saudi J Kidney Dis Transpl [serial online] 2008 [cited 2020 Nov 25];19:983-4. Available from: https://www.sjkdt.org/text.asp?2008/19/6/983/43478
To the Editor,

Death with a functioning kidney is a well recognized cause for the loss of nearly half of the transplanted kidneys. This has recently stimulated UNOS to consider the estimation of the expected life years from transplant (LYFT) upon allocating kidneys from diseased donors. Patients with high LYFT values are expected to have priority especially toward receiving grafts with better quality. LYFT value expre­sses the increased life span (in years) because of receiving a kidney transplant from a par­ticular donor. Its value is affected by multiple recipient and donor factors. It is calculated by using estimated survival years following trans­plant minus estimated survival years if re­mained on dialysis. Adjustment for quality of life was also suggested and carried out by multiplying survival on dialysis by a factor of 0.8. [1]

As no graft allocation problem exists in living donor transplantations, LYFT has not been yet calculated for this group. However, there are other potential benefits from estimating LYFT for the candidate of living donor transplanta­tions, especially if LYFT calculation is carried out and monitored earlier during their late CKD stages. For those planned to receive a kidney from a specific known relative, donor factors as age and gender can be included in the estimation of LYFT at an early stage. The estimation of LYFT for the CKD patients prior to reaching ESRD, may pinpoint an earlier moment at which renal transplantation can be justified for its significant survival benefits over the survival on conservative approach.

Studies have revealed very high mortality for the CKD stages 3b to 5 (i.e. GFR < 45 mL/min). Keith et al reported 5-year mortality of 24.3% and 45.7% in CKD stages 3 and 4, respectively. Only 1.3% of the patients in stage 3 reached ESRD stage during this 5-year follow-up period. 2 Clearly such overall mortality rates of these CKD stages are already much higher than that of many renal transplant patients despite the fact that these transplant patients have reached ESRD prior to receiving their allografts. Fur­thermore, the survival of renal transplant pa­tients receiving their renal graft at an earlier CKD stages would be significantly better than the available rates for the current renal trans­plant patients. Aborting uremia related organs' damage by earlier nephron supplement (i.e. transplantation) is likely to result in renal transplant patients with even lower over-all mortality rates. Data from preemptive renal transplantation where transplantation is carried out usually within CKD stage 5, is obviously supportive for this notion. As only living do­nor (mostly related) kidneys would be offered at CKD stages earlier to dialysis stage, pa­tients' survival benefits are likely result in an even better utilizion of these ideal donors.

Based on available database, LYFT can, apparently, easily be computed for the living donor transplant candidates but at an ESRD stage at which renal transplantation is cur­rently offered. As essentially no transplan­tation is carried out earlier to CKD stage 5, I suggest adopting currently available survival rates for the recipients of living donor kidneys, for the purpose of calculating LYFT at CKD stages earlier to stage 5. This would obviously underestimate LYFT values (survival benefit) when utilized for the CKD patients at stages earlier to stage 5.

On the other hand, building database for the CKD patients similar to that done for the ESRD patients on TX waiting list seems essential for more than just calculating LYFT values that I discuss here. Patients with such high mortality as CKD in stages 3b and be­yond need such database to allow close ana­lysis of the problem. Different cofactors con­tributing to such high mortality rates can be carefully weighed. This would allow accurate estimation of mortality rates for the individual CKD patient. These patients are not different from those dialysis patients listed on the deceased kidney waiting list. They are simi­larly heading toward receiving renal grafts or dying prior to such therapy. USRDS 2003 suggested that the probability of death in such patients is in fact 5 to 10 times that of re­ceiving renal TX. [3]

Renal transplantation can then be appro­priately offered for those CKD individuals at any stage once their calculated LYFT values become remarkably positive in favor of trans­plantation.

 
   References Top

1.OPTN web site: Kidney Allocation Policy Development reports and lectures.  Back to cited text no. 1    
2.Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organi­zation. Arch Intern Med 2004;164(6):659-63.  Back to cited text no. 2    
3.USRDS Annual Report 2003, Atlas of ESRD in the United States, page 38, lines: 23-24 (However, this was a quotation from USRDS 2002 Report).  Back to cited text no. 3    

Top
Correspondence Address:
Nasrulla Abutaleb
Consultant Nephrologist, King Fahad Specialist Hospital, P.O. Box 15215, Dammam 31444
Saudi Arabia
Login to access the Email id


PMID: 18974590

Rights and Permissions




 

Top
 
 
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  
 


 
    References
 

 Article Access Statistics
    Viewed2554    
    Printed52    
    Emailed0    
    PDF Downloaded246    
    Comments [Add]    

Recommend this journal